Meta Pixel

News and Announcements

Jd Sanmed Achieved Reaching Their Milestone With The Development Of Iscope Is Bound To Make An Impact

  • Published September 27, 2021 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

JD Sanmed have reached our milestone of a technical prototype of our product, the iScope. The iScope is a digital medical device that enables General Practitioners to examine patients’ ears, eyes and skin more conveniently than with current instruments, while supporting recording of digital images, and performing billable procedures such as ear wax removal that usually require a referral to a specialist.

We will continue with our customer research to receive more feedback. Previous surveys and interviews of general physicians have indicated consistent responses and strong traction. 82% of doctors are likely to buy a device like iScope as it addresses all needs for medical devices in general practice.

The next major milestone will be the full commercial product, ready to be launched to the market.

We also welcome our new team member, Rachel Boden, who brings in her 20 years experience as an executive in Marketing and Sales. Prior joining us, she has successfully brought several other medical device startups to market. She complements our already strong executive team and we are looking forward to working with her. Rachel’s extensive knowledge and experience will be a great asset to JD Sanmed.

Register Interest

About The Company

JD Sanmed was founded by Dr Olaf Rusoke-Dierich who developed the iScope product as a solution to problems he and his colleagues in General Practice experienced firsthand, every day. He has now engaged Ontogo, who are a team of experienced medical device executives to guide the company through the commercialisation journey.

The iScope has a conservative Serviceable Available Market (SAM) of $264 million, only considering General Practitioners in Australia, USA, France, Germany and the UK. The solution is applicable to other users and in other markets as well, but the intent is to remain focused on the General Practitioner in these countries for the initial version. They are well understood by the current team and yield a very profitable, high growth business.

The path to commercial release is well understood with experienced, Australian medical device design and development houses engaged and ready to take this product through prototyping, development and initial manufacturing.

Our vision is that JD Sanmed will become a leading provider of innovative medical device solutions for Medical General Practitioners worldwide.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now